Skip to main content

Table 3 Overall response rate, PFS, and OS segregated by TMB low/high and PHBR low/high among patients treated with immunotherapy patients (N = 77 with TMB available)

From: MHC-I genotype and tumor mutational burden predict response to immunotherapy

 

Rate of SD with ≥ 6 month/PR/CR1

PFS

OS

Group

N (%)

P value

Median (months)

HR (95% CI)

P value2

Median (months)

HR (95% CI)

P value2

TMB/PHBR (TMB cutoff = 10 mutations/mb)

 Low/high (N = 27) vs. low/low (N = 11)

9 (33%) vs. 2 (18%)

0.45

3.5 vs. 4.2

1.01 (0.48–2.12)

0.99

10.1 vs. 12.0

0.90 (0.37–2.22)

0.82

 Low/high (N = 27) vs. high/high (N = 21)

9 (33%) vs. 9 (43%)

0.56

3.5 vs. 5.8

0.76 (0.54–1.05)

0.09

10.1 vs. 17.2

0.72 (0.47–1.10)

0.12

 Low/high (N = 27) vs. high/low (N = 18)

9 (33%) vs. 14 (78%)

0.006

3.5 vs. 26.8

0.62 (0.47–0.83)

< 0.001

10.1 vs. NR3

0.66 (0.47–0.91)

0.008

 Low/low (N = 11) vs. high/high (N = 21)

2 (18%) vs. 9 (43%)

0.25

4.2 vs. 5.8

0.58 (0.25–1.31)

0.18

12.0 vs. 17.2

0.62 (0.23–1.69)

0.34

 Low/low (N = 11) vs. high/low (N = 18)

2 (18%) vs. 14 (78%)

0.003

4.2 vs. 26.8

0.50 (0.30–0.83)

0.003

12.0 vs. NR3

0.59 (0.34–1.02)

0.049

 High/high (N = 21) vs. high/low (N = 18)

9 (43%) vs. 14 (78%)

0.049

5.8 vs. 26.8

0.39 (0.16–0.91)

0.03

17.2 vs. NR3

0.53 (0.19–1.50)

0.23

TMB/PHBR (TMB cutoff = 20 mutations/mb)

 Low/high (N = 38) vs. low/low (N = 18)

13 (34%) vs. 7 (39%)

0.77

4.1 vs. 4.2

0.89 (0.47–1.67)

0.71

11.1 vs. 12.0

0.81 (0.38–1.73)

0.58

 Low/high (N = 38) vs. high/high (N = 10)

13 (34%) vs. 5 (50%)

0.47

4.1 vs. 3.6

0.96 (0.65–1.41)

0.82

11.1 vs. 17.2

0.76 (0.45–1.31)

0.32

 Low/high (N = 38) vs. high/low (N = 11)

13 (34%) vs. 9 (82%)

0.007

4.1 vs. NR4

0.59 (0.41–0.84)

0.001

11.1 vs. NR5

0.66 (0.44–0.99)

0.03

 Low/low (N = 18) vs. high/high (N = 10)

7 (39%) vs. 5 (50%)

0.70

4.2 vs. 3.6

1.06 (0.44–2.53)

0.90

12.0 vs. 17.2

0.82 (0.26–2.62)

0.74

 Low/low (N = 18) vs. high/low (N = 11)

7 (39%) vs. 9 (82%)

0.052

4.2 vs. NR4

0.46 (0.24–0.86)

0.007

12.0 vs. NR5

0.60 (0.31–1.15)

0.11

 High/high (N = 10) vs. high/low (N = 11)

5 (50%) vs. 9 (82%)

0.18

3.6 vs. NR4

0.16 (0.04–0.64)

0.004

17.2 vs. NR5

0.37 (0.08–1.70)

0.19

  1. 1Thirty-six patients achieved SD with ≥ 6 month/PR/CR
  2. 2P values in Fig. 1 are different as they compare all four categories at the same time
  3. 3Not reached to the median (median follow-up duration, 23.0 months)
  4. 4Not reached to the median (median follow-up duration, 24.6 months)
  5. 5Not reached to the median (median follow-up duration, 27.0 months)
  6. Abbreviations: HR hazard ratio, NR not reached to 50%, OS overall survival, PFS progression-free survival, PHBR Patient Harmonic-mean Best Rank, TMB tumor mutational burden
Back to article page

Genome Medicine

ISSN: 1756-994X

Contact us